Founded in Shenzhen, China, HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.
HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.
Medical Director for Pinnacle Clinical Research and President of Summit Clinical Research. Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford. Past Associate Editor for Hepatology and currently Associate Editor for Alimentary Pharmacology and Therapeutics. Recently retired Colonel in the United States Army with 20 years of service, serving as the Gastroenterology Consultant to the Army Surgeon General. Board certified in both Internal Medicine and Gastroenterology.
Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, and product management. Ms. Melincoff previously served as Senior VP of Business Development at Shire Pharmaceuticals. She also served as board member of Tobira Therapeutics when it was acquired by Allergan.